All rights reserved. No part of this book may be reprinted or reproduced or utilised in any form or by any electronic, mechanical, or other means, now known or hereafter invented, including photocopying and recording, or in any information storage or retrieval system, without permission in writing from the publishers. Enquiries in this regard should be directed to the British Psychological Society.
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
National Collaborating Centre for Mental Health (UK). Drug Misuse: Opioid Detoxification. Leicester (UK): British Psychological Society (UK); 2008. (NICE Clinical Guidelines, No. 52.)
With a range of practical experience relevant to drug misuse in the GDG, members were appointed because of their understanding and expertise in healthcare for people who misuse drugs and support for their families and carers, including: scientific issues; health research; the delivery and receipt of healthcare, along with the work of the healthcare industry; and the role of professional organisations and organisations for people who misuse drugs and their families and carers.
To minimise and manage any potential conflicts of interest, and to avoid any public concern that commercial or other financial interests have affected the work of the GDG and influenced guidance, members of the GDG must declare as a matter of public record any interests held by themselves or their families that fall under specified categories (see below). These categories include any relationships they have with the healthcare industries, professional organisations and organisations for people who misuse drugs and their families and carers.
Individuals invited to join the GDG were asked to declare their interests before being appointed. To allow the management of any potential conflicts of interest that might arise during the development of the guideline, GDG members were also asked to declare their interests at each GDG meeting throughout the guideline development process. The interests of all the members of the GDG are listed below, including interests declared prior to appointment and during the guideline development process.
CATEGORIES OF INTEREST
- Paid employment
- Personal interests related to drug misuse: payment in cash or kind and/or funding from the drug misuse-related healthcare industry, including consultancies, grants, fee-paid work and shareholdings or other beneficial interests.
- Personal interests not specifically related to drug misuse: any other payment and/or funding from the healthcare industry, including consultancies, grants and shareholdings or other beneficial interests.
- Non-personal interests: funding from the healthcare industry received by the GDG member’s organisation or department, but where the GDG member has not personally received payment, including fellowships and other support provided by the healthcare industry.
- Personal non-monetary interests: these include, but are not limited to, clear opinions or public statements you have made about drug misuse, holding office in a professional organisation or advocacy group with a direct interest in drug misuse, other reputational risks relevant to drug misuse.
- Personal family interests: payments in cash or kind that were received by a member of your family.
- Other interests relating to drug misuse: funding from governmental or nongovernmental organisations, charities, and so on, and/or ownership in a company that provides therapy or treatments likely to be covered in the guideline.
Declarations of interest | |
---|---|
Dr Clare Gerada – Chair, Guideline Development Group | |
Employment | General Practitioner, Lambeth Primary Care, Trust, London Practice; Primary Care Lead for Drug Misuse and Chair at the Royal College of General Practitioners |
Personal interests related to drug misuse | Member of Suboxone Expert Group at Schering-Plough (attended two meetings, received payment of £1000); member of Specialist Opioid Advisory Group at Napp Pharmaceuticals (reimbursed expenses for attending only) |
Personal interests not specifically related to drug misuse | Member of Hepatitis C Expert Group at Roche (attended two meetings, received payment of £800) |
Non-personal interests | Royal College of General Practitioners received funding from Schering-Plough for educational material |
Personal non-monetary interests | Spoken publicly about heroin treatment: against heroin treatment until methadone treatment is adequately resourced |
Personal family interests | None |
Other interests related to drug misuse | Consultancy fees from Royal College of General Practitioners for training GPs in substance misuse; Advisor to Royal College of General Practitioners on all matters relating to substance misuse; Given evidence to General Medical Council on GPs’ level of performance. Attended number of meetings run by Schering-Plough looking at feasibility of Suboxone as a treatment in the UK Attended Roche-funded hepatitis C meeting |
Mrs Pauline Bissett | |
Employment | Retired (previously Chief Executive, Broadway Lodge until December 2006) |
Personal interests related to drug misuse | None |
Personal interests not specifically related to drug misuse | None |
Non-personal interests | None |
Personal non-monetary interests | None |
Personal family interests | None |
Other interests related to drug misuse | None |
Mr Neil Connelly | |
Employment | Voluntary Support Worker, Littledale Hall Therapeutic Community, Lancaster |
Personal interests related to drug misuse | None |
Personal interests not specifically related to drug misuse | None |
Non-personal interests | None |
Personal non-monetary interests | None |
Personal family interests | None |
Other interests related to drug misuse | None |
Dr Paul Davis | |
Employment | Consultant Lead Clinical Psychologist and Head of Psychology for Substance Misuse Services, Camden and Islington Mental Health and Social Care Trust |
Personal interests related to drug misuse | None |
Personal interests not specifically related to drug misuse | None |
Non-personal interests | None |
Personal non-monetary interests | Employed 1 day per week by National Treatment Agency for Substance Misuse as Clinical Psychology Advisor (September 2006–2008) |
Personal family interests | None |
Other interests related to drug misuse | Current grant funded projects: A study of the feasibility of routine screening and ‘Stepped Care’ psychological interventions with hazardous and problem drinkers in three inner London General Hospitals (London Health Action Zone 2003–2005, £47,000) |
Ms Vivienne Evans | |
Employment | Chief Executive, Adfam; Non-executive director of Charnwood and North West Leicestershire Primary Care Trust |
Personal interests related to drug misuse | None |
Personal interests not specifically related to drug misuse | None |
Non-personal interests | £6000 sponsorship from Schering-Plough to cover expenses of hosting Adfam’s 21st birthday celebration, October 2005 |
Personal non-monetary interests | None |
Personal family interests | None |
Other interests related to drug misuse | None |
Dr Emily Finch | |
Employment | Addiction Psychiatrist, South London and Maudsley NHS Foundation Trust; Clinical Team Lead, National Treatment Agency for Substance Misuse |
Personal interests related to drug misuse | None |
Personal interests not specifically related to drug misuse | None |
Non-personal interests | None |
Personal non-monetary interests | Trustee of Phoenix House |
Personal family interests | None |
Other interests related to drug misuse | Trustee of Phoenix House; Seconded two days per week to the NTA (October 2004 – January 2007) |
Professor Robert Forrest | |
Employment | Consultant in Clinical Chemistry and Toxicology, Sheffield Teaching Hospitals NHS Foundation Trust |
Personal interests related to drug misuse | None |
Personal interests not specifically related to drug misuse | None |
Non-personal interests | None |
Personal non-monetary interests | President of Forensic Science Society; Assistant Deputy Coroner, South Yorkshire (West); Programme Chair, Jurisprudence Section, American Academy of Forensic Sciences; expert witness in many cases where the issues are relevant to drug misuse; member of the editorial board for Science and Justice; member of Secretary of State’s Medical Advisory Committee on Alcohol, Driving and Drugs |
Personal family interests | None |
Other interests related to drug misuse | Consultancy work (remitted to employer) for Forensic Alliance Ltd, now part of the Laboratory of the Government Chemist (LGC) |
Dr Eilish Gilvarry | |
Employment | Clinical Director, Newcastle Drug and Alcohol Unit, Newcastle upon Tyne |
Personal interests related to drug misuse | None |
Personal interests not specifically related to drug misuse | None |
Non-personal interests | None |
Personal non-monetary interests | None |
Personal family interests | None |
Other interests related to drug misuse | None |
Mr David Harding-Price | |
Employment | Team Coordinator, Community Mental Health Team, Skegness, Lincolnshire |
Personal interests related to drug misuse | None |
Personal interests not specifically related to drug misuse | None |
Non-personal interests | Eli Lilly 2005 funded mental health educational event at RCN congress; Janssen-Cilag 2005 sponsored European mental health educational conference |
Personal non-monetary interests | None |
Personal family interests | None |
Other interests related to drug misuse | None |
Mr Paul Hawkins | |
Employment | None |
Personal interests related to drug misuse | None |
Personal interests not specifically related to drug misuse | None |
Non-personal interests | Member of executive board for Cumbria Alcohol and Drugs Advisory Service |
Personal non-monetary interests | None |
Personal family interests | None |
Other interests related to drug misuse | None |
Dr Anne Lingford-Hughes | |
Employment | Reader in Biological Psychiatry and Addiction, Academic Unit of Psychiatry, University of Bristol; Addiction Psychiatrist, Avon and Wiltshire Mental Health Trust |
Personal interests related to drug misuse | None |
Personal interests not specifically related to drug misuse | Member of core faculty and steering group for Bristol-Myers Squibb, 2004, £2000; Honorarium from Janssen-Cilag for presentation, 2005; Honorarium from Bristol-Myers Squibb for plenary lecture, £499.23, 2007; Consultancy fee from Sanofi-Aventis, £1000, 2006; Health hearing systems for Johnson and Johnson Pharmaceutical services, 2003, £1451.72; Unrestricted grants for research; Merck, £50,000, 2004; Wyeth, £70,000, 2000 |
Non-personal interests | Psychopharmacology Unit, University of Bristol: Fellowship – Lundbeck; Within last 5 years department received various unrestricted grants from GSK, Astra-Zeneca, MSD, Wyeth, Novartis, Bristol-Myers Squibb |
Personal non-monetary interests | Hon General Secretary of British Association for Psychopharmacology (BAP) – responsible for educational activities including opioid detoxification and coordinated BAP Consensus Guidelines, 2004, covering management of opioid detoxification. |
Personal family interests | None |
Other interests related to drug misuse | None |
Ms Jan Palmer | |
Employment | Nurse Consultant, Clinical Substance Misuse Lead, Offender Health |
Personal interests related to drug misuse | None |
Personal interests not specifically related to drug misuse | None |
Non-personal interests | None |
Personal non-monetary interests | None |
Personal family interests | None |
Other interests related to drug misuse | None |
Mrs Kay Roberts | |
Employment | Pharmacist; Chairman, PharMAG |
Personal interests related to drug misuse | Wells Healthcare (for Schering-Plough) consultancy fees for training events; advisory board for Scotland: Suboxone, £800 in 2002, £360 in 2003; member of advisory board for Frontier Medical |
Personal interests not specifically related to drug misuse | None |
Non-personal interests | PharMAG receives in sponsorship and printing costs: Britannia Pharmaceuticals £250 per annum Reckitt Benckiser Ltd £1500, 2006; Rosemont Pharmaceuticals Ltd £1350, 2003–2005 Frontier Medical Ltd £250 per annum Cardinal Healthcare (Martindale Pharmaceuticals) £2000, 2006 |
Personal non-monetary interests | Royal College of General Practitioners, Lead Pharmacist (England) on Management of Substance Misuse in Primary Care; Royal College of General Practitioners (Scotland) tutor for Certificate in Management of Substance Misuse in Primary Care; Advisor to the Royal Pharmaceuticals Society of Great Britain on substance misuse; consultancy work for National Treatment Agency for Substance Misuse; member of the advisory council on misuse of drugs; member of UK Harm Reduction Alliance; member of Glasgow Children’s Hearings Panel; member of International Harm Reduction Association; member of Scottish Medico-legal Society |
Personal family interests | None |
Other interests related to drug misuse | None |
NCCMH STAFF
Mr Stephen Pilling – Facilitator, Guideline Development Group | |
Employment | Joint Director, NCCMH; Director, Centre for Outcomes Research and Effectiveness, University College London; Consultant Clinical Psychologist and Deputy Head of Psychology Services, Camden and Islington Mental Health and Social Care Trust |
Personal interests related to drug misuse | None |
Personal interests not specifically related to drug misuse | Lecture for UK Psychiatric Pharmacy Group, October 2006, £300 including expenses; Lecture at Andrew Simms Centre, Leeds, December 2006, £300 including expenses |
Non-personal interests | Grants for production of clinical guidelines and evidence-related practice: British Psychological Society Clinical Effectiveness Programme with Professor P. Fonagy and Professor S. Michie supporting production of NICE guidelines and related policy implementation work (£5.4 million, 2001–2010) Health service research grants: NHS Service Development and Organisation Research and Development Programme developing evidence-based and acceptable stepped-care systems in mental healthcare, an operational research project with Professor D. Richards, Professor S. Gallivan, Dr S. Gilbody, Professor K. Lovell, Dr J. Cape, Dr P. Bower and Ms J. Leibowitz (£299,642, 2006–2009); NHS Service Development and Organisation Research and Development Programme – The 100 Ward Study: a National Survey of Psychiatric Inpatient Unit Morale with Dr S. Johnson, Professor P. Bebbington, Professor M. King, Professor S. Woods, Professor N. Wellman, Dr D. Osborn and Dr R. Arraya (£296,999, 2006–2009) |
Personal non-monetary interests | None |
Personal family interests | None |
Other interests related to drug misuse | None |
Ms Sarah Hopkins | |
Employment | Project Manager, NCCMH |
Personal interests related to drug misuse | None |
Personal interests not specifically related to drug misuse | None |
Non-personal interests | None |
Personal non-monetary interests | None |
Personal family interests | None |
Other interests related to drug misuse | None |
Ms Rebecca King | |
Employment | Project Manager, NCCMH (2005–2006) |
Personal interests related to drug misuse | None |
Personal interests not specifically related to drug misuse | None |
Non-personal interests | None |
Personal non-monetary interests | None |
Personal family interests | None |
Other interests related to drug misuse | None |
Mr Ryan Li | |
Employment | Research Assistant, NCCMH |
Personal interests related to drug misuse | None |
Personal interests not specifically related to drug misuse | None |
Non-personal interests | None |
Personal non-monetary interests | None |
Personal family interests | None |
Other interests related to drug misuse | None |
Dr Nicholas Meader | |
Employment | Systematic Reviewer, NCCMH |
Personal interests related to drug misuse | None |
Personal interests not specifically related to drug misuse | None |
Non-personal interests | None |
Personal non-monetary interests | None |
Personal family interests | None |
Other interests related to drug misuse | None |
Ms Poonam Sood | |
Employment | Research Assistant, NCCMH |
Personal interests related to drug misuse | None |
Personal interests not specifically related to drug misuse | None |
Non-personal interests | None |
Personal non-monetary interests | None |
Personal family interests | None |
Other interests related to drug misuse | None |
Ms Sarah Stockton | |
Employment | Information Scientist, NCCMH |
Personal interests related to drug misuse | None |
Personal interests not specifically related to drug misuse | None |
Non-personal interests | None |
Personal non-monetary interests | None |
Personal family interests | None |
Other interests related to drug misuse | None |
Dr Clare Taylor | |
Employment | Editor, NCCMH |
Personal interests related to drug misuse | None |
Personal interests not specifically related to drug misuse | None |
Non-personal interests | None |
Personal non-monetary interests | None |
Personal family interests | None |
Other interests related to drug misuse | None |
Mr Loukas Xaplanteris | |
Employment | Health Economist, NCCMH |
Personal interests related to drug misuse | None |
Personal interests not specifically related to drug misuse | None |
Non-personal interests | None |
Personal non-monetary interests | None |
Personal family interests | None |
Other interests related to drug misuse | None |
- DECLARATIONS OF INTEREST BY GUIDELINE DEVELOPMENT GROUP MEMBERS - Drug MisuseDECLARATIONS OF INTEREST BY GUIDELINE DEVELOPMENT GROUP MEMBERS - Drug Misuse
- Autosomal dominant nocturnal frontal lobe epilepsy 4Autosomal dominant nocturnal frontal lobe epilepsy 4MedGen
- Autosomal dominant nocturnal frontal lobe epilepsyAutosomal dominant nocturnal frontal lobe epilepsyMedGen
Your browsing activity is empty.
Activity recording is turned off.
See more...